Drug Delivery Technologies: Commercial Prospects 2013-2023

©noticeThis material is copyright 2010 by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

Drug Delivery Technologies: Commercial Prospects 2013-2023

www.visiongain.com

Contents

1.1 Drug Delivery Technology: Market Review

1.2 Aims, Scope and Format of Report

1.2.1 Chapter Outlines

1.3 Research and Analysis Methods

2.1 Introduction to Drug Delivery Technologies (DDT)

2.2 Types of Technologies for Drug Delivery

2.2.1 Sustained/Controlled Release Systems

2.2.2 Injection

2.2.3 Needle Free Injection

2.2.4 Pulmonary, Buccal and Nasal Delivery

2.2.5 Pills and Capsules

2.3 Biopharmaceuticals

2.3.1 Overview of the Biologicals Market

2.3.2 The Biological Drug Industry is Strong

2.4 Biotech Drugs with Associated Drug Delivery Technologies

2.4.1 Pegylated Interferons

2.4.2 Crowded Insulin Market Has Forced Investment in DDT

2.5 Exubera - Case Study for Alternative Biological Delivery Methods

2.5.1 The First Inhaled Insulin

2.5.2 Description and Development History

2.5.3 Generex and MannKind Developing Next-Generation Oral Insulins

2.5.4 Challenges Facing Afrezza and Oral-lyn

2.6 The Main Challenges for Biological Drug Delivery

2. Introduction

1. Executive Summary

www.visiongain.com

Contents

3.1 The World Drug Delivery Technology Market: Overview

3.2 Growing Market for Drug Delivery Technology and Services

3.2.1 Revenue Forecast for Overall Drug Delivery Technology Market, 2012-2017

3.2.2 Revenue Forecast for Overall Drug Delivery Market, 2018-2023

3.3 Breakdown of the Global Drug Delivery Technology Market

3.3.1 Revenue Forecast for Oral Drug Delivery Technology, 2012-2017

3.3.2 Revenue Forecast for Oral Drug Delivery Technology, 2018-2023

3.3.3 Revenue Forecast for Inhalation Drug Delivery Technology, 2012-2017

3.3.4 Revenue Forecast for Inhalation Drug Delivery Technology, 2018-2023

3.3.5 Revenue Forecast for Transdermal Drug Delivery Technology, 2012-2017

3.3.6 Revenue Forecast for Transdermal Drug Delivery Technology, 2018-2023

3.3.7 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2012-2017

3.3.8 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2018-2023

3.3.9 Revenue Forecast for Ocular Drug Delivery Technology, 2012-2017

3.3.10 Revenue Forecast for Ocular Drug Delivery Technology, 2018-2023

3.3.11 Revenue Forecast for Nasal Drug Delivery Technology, 2012-2017

3.3.12 Revenue Forecast for Nasal Drug Delivery Technology, 2018-2023

3.4 Leading National Markets for Drug Delivery Technology

3.4.1 The US Drug Delivery Technology Market, 2013-2023

3.4.2 The Japanese Drug Delivery Technology Market, 2013-2023

3.4.3 The Leading European Drug Delivery Technology Markets, 2013-2023

3.4.4 Emerging-Economy Drug Delivery Technology Markets

3.4.5 The Chinese Drug Delivery Technology Market, 2013-2023

3.4.6 The Indian Drug Delivery Technology Market, 2013-2023

3. The World Drug Delivery Technology Market to 2023

www.visiongain.com

Contents

4.1 Therapeutic Areas Offering Growth Opportunities

4.1.1 Sales of Biologics Will Stimulate Developments in Drug Delivery

4.1.2 Leading Segments of Biological Drugs Market in 2012

4.1.3 Monoclonal Antibodies Lead the Biologics Market

4.1.3.1 Prospects for Monoclonal Antibodies and Implications for Drug Delivery

4.1.4 The Human Insulins Class Will Exhibit Strong Growth

4.1.5 Erythropoietin Products – What are the Future Prospects?

4.1.5.1 Erythropoietin Products Forecast, 2013-2023

4.1.6 The Interferons Class Will Show an Increase in Revenues from 2012-2017

4.1.6.1 Long-Term Forecast for the Interferons Class

4.1.7 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2013-2023

4.1.8 Recombinant Coagulation Factors Will Show Steady Growth

4.1.9 Other Therapeutic Proteins

4.1.10 The Biosimilars Market, 2012

4.1.10.1 Forecast for the Global Biosimilars Market, 2013-2023

4.1.11 Forecast for the Vaccines Market, 2013-2023

4.2 The Drug Delivery Technology Market: Conclusions

4.2.1 A Rapidly Expanding Segment of the Global Pharma Industry

5.1 Introduction

5.2 Leading Oral Drug Delivery Companies

5.2.1 Applied Pharma Research (APR)

5.2.1.1 Overview

5.2.1.2 Therapeutic Areas and Technology

5. Prominent Companies in the Drug Delivery Technology Market

4. Drug Classes That Can Benefit from Advances in Drug Delivery

www.visiongain.com

Contents 5.2.1.3 MonoSol Rx Enters into Licensing Agreement with Vestiq Pharmaceuticals for

Zuplenz

5.2.2 Catalent Pharma Solutions

5.2.2.1 Overview

5.2.2.2 Catalent's Oral Drug Delivery Technology

5.2.2.3 Catalent's Customer Base

5.2.2.4 Manufacturing Capabilities

5.2.2.5 Revenues

5.2.2.6 Catalent Pharma Acquires Clinical Trial Supplies Business

5.2.2.7 Catalent’s Actions and Progress in 2012

5.2.3 Emisphere Technologies

5.2.3.1 Overview

5.2.3.2 Emisphere's Eligen Technology

5.2.3.3 Emisphere's Pipeline Products

5.2.3.4 Emisphere's Partnered Programmes

5.2.3.5 Revenues

5.2.3.6 Future Outlook

5.2.4 Ethypharm

5.2.4.1 Overview

5.2.4.2 Ethypharm's Proprietary Technologies

5.2.4.3 Products on the Market

5.2.4.4 Development Pipeline

5.2.5 Aptalis

5.2.5.1 Overview

5.2.5.2 Aptalis's Drug Delivery Platforms

5.2.5.3 Products for Out-Licensing

5.2.5.4 Revenue


5.2.6 Glycologic

5.2.6.1 Overview

www.visiongain.com

Contents 5.2.6.2 Glycologic Technology Platform

5.2.6.3 Pipeline Products


5.3 Inhaled Drug Delivery

5.3.1 3M Drug Delivery Systems

5.3.1.1 Overview

5.3.1.2 Protein and Peptide Delivery

5.3.1.3 Excipient Technology for CFC-Free Inhalers

5.3.1.4 Actuator Technology for MDIs

5.3.1.5 Particle Engineering Technology

5.3.1.6 Revenues

5.3.2 Aradigm Corp.

5.3.2.1Overview

5.3.2.2 AERx Drug Delivery System

5.3.2.3 Collaborations


5.3.2.5 Revenues

5.3.3 Vectura Group

5.3.3.1 Overview

5.3.3.2 Proprietary Technologies


5.3.3.4 Revenues

5.4 Injectable Drug Delivery

5.4.1 Alkermes

5.4.1.1Overview

5.4.1.2 Proprietary Technology Platforms

5.4.1.3 Product Pipeline

5.4.1.4 Revenues

5.4.2 Pacira Pharmaceuticals

5.4.2.1 Overview

www.visiongain.com

Contents 5.4.2.2 Injectable Sustained-Release Technology

5.4.2.3 Products

5.4.2.4 Pipeline

5.4.2.5 Revenues


5.4.3 Antares Pharma

5.4.3.1 Overview

5.4.3.2 Technology

5.4.3.2.1 Pressure Assisted Injection Devices

5.4.3.2.2 Transdermal Gel System

5.4.3.3 Products

5.4.3.3.1 Vision

5.4.3.3.2 Vibex

5.4.3.3.3 Pen Injector

5.4.3.4 Pipeline Technologies

5.4.3.4.1 Vibex MTX

5.4.3.5 Manufacturing

5.4.3.6 Revenues


5.4.4 Bioject Medical Technologies

5.4.4.1 Technology

5.4.4.2 Products

5.4.4.2.1 Biojector 2000

5.4.4.2.2 Vitajet

5.4.4.2.3 ZetaJet

5.4.4.3 Pipeline Technologies

5.4.4.3.1 Intradermal Pen Injector

5.4.4.3.2 Iject

5.4.4.3.3 Jupiter Jet

5.4.4.4 Manufacturing

www.visiongain.com

Contents 5.4.4.5 Collaborations

5.4.4.5.1 MPI Research

5.4.4.5.2 World Health Organization (WHO)

5.4.4.6 Revenues

5.5 Transdermal Drug Delivery

5.5.1 3M

5.5.1.1 Overview

5.5.1.2 Transdermal Systems

5.5.2 Altea Therapeutics

5.5.2.1 Overview

5.5.2.2 Altea's PassPort Technology Platform

5.5.2.3 Therapeutic Focus

5.5.2.4 Nitto Denko Acquires Altea Therapeutics Assets

5.5.3 Intercell

5.5.3.1 Overview

5.5.3.2 Vaccine Patch Technology Platform

5.5.3.3 Intercell's Strategic Alliances

5.5.3.4 Revenues


5.5.4 NanoPass Technologies

5.5.4.1 Overview

5.5.4.2 Technology Platform

5.5.4.3 The MicronJet Needle

5.5.4.4 NanoCare

5.5.5 Noven Pharmaceuticals

5.5.5.1 Overview

5.5.5.2 Key Products

5.5.5.3 Transdermal Pipeline

5.5.5.4 Revenues

5.6 Transmucosal Drug Delivery

www.visiongain.com

Contents 5.6.1 Overview of Technology

5.6.2 Cima Labs (Cephalon)

5.6.2.1 Overview

5.6.2.2 Cima's Transmucosal Drug Delivery Technologies

5.6.2.3 Products

5.6.3 Columbia Laboratories

5.6.3.1 Overview

5.6.3.2 Bioadhesive Delivery Technology

5.6.3.3 Products

5.6.3.4 Revenue


5.6.4 Generex Biotechnology Corporation

5.6.4.1 Overview

5.6.4.2 Products


5.6.4.4 Revenue

5.7 Implant Technology

5.7.1 Overview of Technology

5.7.2 pSivida Corp.

5.7.2.1 Overview

5.7.2.2 Technologies and Products

5.7.2.2.1 Durasert Technology System

5.7.2.2.2 BioSilicon Technology System

5.7.2.2.3 CODRUG Technology System

5.7.2.3 Products

5.7.2.3.1 Iluvian Approved in Europe

5.7.2.4 Revenues

www.visiongain.com

Contents

6.1 Analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT)

6.2 Patent Expiry Will Drive Biological Drug Delivery

6.2.1 Biosimilars Legislation Encourages Innovation

6.2.2 As Patents Expire, Competition Will Increase

6.3 Competitive and Lucrative Monoclonal Antibody Market Will Drive Sales

6.4 Biological Drug Delivery Technology is Already Established

6.4.1 Pegylation Has Imparted Benefits

6.4.2 New Delivery Methods for Insulin?

6.4.3 Nanotechnology Can Benefit Biological Drug Delivery

6.5 Will Regulatory Authorities Hold Back the Market?

6.5.1 Risk-Conscious FDA and EMA Will Make Approval Difficult?

6.5.2 Choice between New Technology or a New Drug? Is a Rethink Needed?

6.6 New Delivery Methods for Biologicals Must be Cost Effective and Appropriate

6.7 Injection is Still the Major Form of Delivery

6.8 Next-Generation Drugs May Limit Drug Delivery Revenues

6.8.1 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines

6.8.2 New Chemical Entities Could Restrict Biotech Growth

6.9 The Biological Drug Delivery Market Offers Great Potential, But Care is Needed

7.1 Professor Sven Frøkjær, Dean, Faculty of Pharmaceutical Sciences, University of

Copenhagen, Denmark

7.1.1 Market Value for Drug Delivery Systems

7.1.2 Key Benefits for Patients

7.1.3 On Emerging Technologies

7. Research Interviews from Our Survey

6. Drivers, Restraints and Trends in Drug Delivery

www.visiongain.com

Contents 7.1.4 On Nanotechnology

7.1.5 On Different Systems

7.1.6 Main Challenges Facing the Sector

7.1.7 On Nanoparticle Systems and Drug Delivery

7.1.8 Systems on the Market

7.1.9 Diseases of Interest

7.1.10 Therapeutic Areas Offering Opportunities

7.2 Dr Bill Lambert, Ph.D., Senior Vice President, Pharmaceutical Development, Pacira

Pharmaceuticals, San Diego, CA, USA

7.2.1 On Pacira and Drug Delivery Technology

7.2.2 Liposomal Drug Delivery

7.2.3 Applications of DepoFoam Technology

7.2.4 On Pacira's Products

7.2.5 Pipeline DDT Platforms

7.2.6 On the Market for Drug Delivery Technology

7.2.7 Therapeutic Areas Offering Market Opportunities

7.2.8 Challenges Facing Drug Delivery Industry

7.2.9 Comparing DepoFoam with Other Controlled-Release Systems

7.2.10 Mode of Delivery

7.2.11 Insulin and Liposomal Drug Delivery

7.2.12 R&D and Technologies Likely to be on Market in Future

7.3 Mr David Harris, Principal Consultant at Team Consulting Limited, UK

7.3.1 Current Market Value for Drug Delivery Systems

7.3.2 On Key Unmet Needs

7.3.3 On Research Focus in the 10-15 Years

7.3.4 On Main Challenges Facing the Sector

7.3.5 On Therapeutic Areas Offering Opportunities

7.3.6 On Pipeline Developments

7.4 Dr Ronan Mac Loughlin, Scientist at Aerogen, Galway, Ireland

7.4.1 Current Market Value for Drug Delivery Systems

www.visiongain.com

Contents 7.4.2 On Aerogen and its Drug Delivery Systems

7.4.3 On Key Unmet Needs

7.4.4 On Research Focus in the Next 10-15 Years

7.4.5 On Main Challenges Facing the Sector

7.4.6 On Therapeutic Areas Offering Opportunities

7.4.7 On Pipeline Developments

7.5 Mr. John Turanin, VP and General Manager, Zogenix Technologies, CA, USA

7.5.1 On Current State of the Market

7.5.2 On Patient Awareness and Needle-free Injectable Technology

7.5.3 On JV/M&A and Zogenix

7.5.4 Zogenix’s Product Portfolio and Technology

7.5.5 On Competing Technologies and Market Share

7.5.6 On Adoption of Zogenix’s Technology

7.5.7 On The Future Needle-Free Injection Devices

7.5.8 On Major Challenges Facing Needle-Free Injection Devices

7.5.9 On Future Growth in the Sector

7.6 Mr. Charles Potter, CBO, Glide Pharma, Oxford, UK

7.6.1 On Growth and Market Potential

7.6.2 On Patient Power and DTC Marketing

7.6.3 Glide SDI & Other Technologies

7.6.4 On Competition from Transdermal & Inhalation Technologies

7.6.5 Market Demand & Future Outlook

7.6.6 On Future Technology Trends

7.6.7 On Future Market Potential

7.7 Ms. Heather Potters, Chairman, PharmaJet, Colorado, USA

7.7.1 On Needle-Free Drug Delivery Technology Market

7.7.2 On M&A and JV Strategy for Growth

7.7.3 On PharmaJet’s Leading Products

7.7.4 On Equivalence of Fractional and Full Dose Delivery

7.7.5 Patient Awareness About Jet Injectors

www.visiongain.com

Contents 7.7.6 Unmet Needs in the Jet Injectors Market

7.7.7 Major Challenges Faced by Jet Injectors Market

7.7.8 The Outlook for Needle-Free Technology Market

8.1 The Market Shows Potential for Strong Revenue Growth

8.2 Commercial Drivers for Drug Delivery Technology

8.3 Prominent Companies in the Market

8.4 Future Outlook and Concluding Remarks

8. Conclusions of Our Research and Analyses

www.visiongain.com

Contents

Table 2.1 Top 10 Biotech Drugs, 2012

Table 2.2 Top 10 Biopharma Companies: Revenues & R&D Expenditure, 2011

Table 2.3 Amino Acid Changes for Human Insulin Analogues

Table 3.1 Drug Delivery Technology Market: World Revenues, 2012-2017

Table 3.2 Drug Delivery Technology Market: World Revenues, 2018-2023

Table 3.3 Oral Drug Delivery Technology Market: World Revenues, 2012-2017

Table 3.4 Oral Drug Delivery Technology Market: World Revenues, 2018-2023

Table 3.5 Inhalation Drug Delivery Technology Market: World Revenues, 2012-2017

Table 3.6 Inhalation Drug Delivery Technology Market: World Revenues, 2018-2023

Table 3.7 Transdermal DDT Market: World Revenues, 2012-2017

Table 3.8 Transdermal DDT Market: World Revenues, 2018-2023

Table 3.9 Injectable/Implants DDT Market: World Revenues, 2012-2017

Table 3.10 Injectable/Implants DDT Market: World Revenues, 2018-2023

Table 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2012-2017

Table 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2018-2023

Table 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2012-2017

Table 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2018-2023

Table 3.15 Drug Delivery Technology Submarkets: World Revenues, 2012-2017

Table 3.16 Drug Delivery Technology Submarkets: World Revenues, 2018-2023

Table 3.17 Drug Delivery Technology: Leading National Market Forecasts, 2012-2023

Table 4.1 Leading Drug Classes Driving the Drug Delivery Technology Market, 2011 and 2012

Table 4.2 Some Leading Monoclonal Antibody Drugs, 2013

Table 4.3 Monoclonal Antibodies Market: World Sales Forecast, 2012-2017

Table 4.4 Monoclonal Antibodies Market: World Sales Forecast, 2018-2023

Table 4.5 Insulins Market: World Sales Forecast, 2012-2017

Table 4.6 Insulins Market: World Sales Forecast, 2018-2023

List of Tables

www.visiongain.com

Contents Table 4.7 Erythropoietins Market: World Sales Forecast, 2012-2017

Table 4.8 Erythropoietins Market: World Sales Forecast, 2018-2023

Table 4.9 Some Interferon Drugs, 2013

Table 4.10 Interferons Market: World Sales Forecast, 2012-2017

Table 4.11 Interferons Market: World Sales Forecast, 2018-2023

Table 4.12 G-CSF Market: World Sales Forecast, 2012-2017

Table 4.13 G-CSF Market: World Sales Forecast, 2018-2023

Table 4.14 Some Recombinant Coagulation Factors, 2013

Table 4.15 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2017


Table 4.17 Some Human Growth Hormones, 2013

Table 4.18 Some Immunosuppressant Products, 2013

Table 4.19 Other Therapeutic Proteins Market: World Sales Forecast, 2012-2017

Table 4.20 Other Therapeutic Proteins Market: World Sales Forecast, 2018-2023

Table 4.21 Some Biosimilar Drugs, 2013

Table 4.22 Biosimilars Market: World Sales Forecast, 2012-2017

Table 4.23 Biosimilars Market: World Sales Forecast, 2018-2023

Table 4.24 Some Vaccines Products, 2013

Table 4.25 Vaccines Market: World Sales Forecast, 2012-2017

Table 4.26 Vaccines Market: World Sales Forecast, 2018-2023

Table 5.1 Aradigm's Product Pipeline, 2013

Table 5.2 Alkermes' Product Pipeline, 2013

Table 5.3 Antares Pharma Licensing Partnerships, 2013

Table 5.4 Antares Pharma: Summary of Technology, 2013

Table 5.5 Bioject: Summary of Technologies, 2013

Table 5.6 Intercell's Strategic Alliances, 2013

Table 5.7 Noven's Marketed & Pipeline Transdermal Products, 2013

Table 6.1 SWOT Analysis of the Drug Delivery Industry and Market, 2013

Table 6.2 Some Leading Drugs Expected to Lose Patent Protection, 2012-2015

Table 6.3 Monoclonal Antibody Therapies Approved by the US FDA, 1986-2003

www.visiongain.com

Contents Table 6.4 Monoclonal Antibody Therapies Approved by the US FDA, 2004-2010

Table 6.5 Leading Biologic Drug Types, 2012

Table 8.1 Drug Delivery Technology Market: World Revenues, 2012, 2013, 2017, 2019, 2021 &

2023

www.visiongain.com

Contents

Figure 3.1 Drug Delivery Technology Market: World Revenues, 2012-2017

Figure 3.2 Drug Delivery Technology Market: World Revenues, 2018-2023

Figure 3.3 Oral Drug Delivery Technology Market: World Revenues, 2012-2017

Figure 3.4 Oral Drug Delivery Technology Market: World Revenues, 2018-2023

Figure 3.5 Inhalation DDT Market: World Revenues, 2012-2017

Figure 3.6 Inhalation DDT Market: World Revenues, 2018-2023

Figure 3.7 Transdermal DDT Market: World Revenues, 2012-2017

Figure 3.8 Transdermal DDT Market: World Revenues, 2018-2023

Figure 3.9 Injectable/Implants DDT Market: World Revenues, 2012-2017

Figure 3.10 Injectable/Implants DDT Market: World Revenues, 2018-2023

Figure 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2012-2017

Figure 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2018-2023

Figure 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2012-2017

Figure 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2018-2023

Figure 3.15 Drug Delivery Technology Submarkets: World Revenues, 2012-2023

Figure 3.16 US DDT Market: Sales Forecast, 2012-2023

Figure 3.17 Other Leading DDT National Markets: Sales Forecasts, 2012-2023

Figure 3.18 DDT Sales Shares in Leading National Markets, 2012




Figure 4.1 Monoclonal Antibodies Market: World Sales Forecast, 2012-2023

Figure 4.2 Insulins Market: World Sales Forecast, 2012-2023

Figure 4.3 Erythropoietins Market: World Sales Forecast, 2012-2023

Figure 4.4 Interferons Market: World Sales Forecast, 2012-2023

Figure 4.5 G-CSF Market: World Sales Forecast, 2012-2023

List of Figures

www.visiongain.com

Contents Figure 4.6 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2023

Figure 4.7 Other Therapeutic Proteins Market: World Sales Forecast, 2012-2023

Figure 4.8 Biosimilars Market: World Sales Forecast, 2012-2023

Figure 4.9 Vaccines Market: World Sales Forecast, 2012-2023

Figure 6.1 Different Approaches to Biological Drug Delivery, 2013

Figure 8.1 Drug Delivery Technology Market: World Revenues by Category, 2012, 2013, 2017,

2019, 2021 and 2023

Figure 8.2 Drug Delivery Technology Market: World Revenues, 2011, 2012, 2016, 2018, 2020 &

2023

Figure 8.3 Drug Delivery Technology Market: World Revenue Shares by Category, 2012

www.visiongain.com

Contents

3M

Abbott Laboratories

Actelion Pharmaceuticals

Aeras

Aerogen

Alexion Pharmaceuticals

Alimera Sciences

Alkermes

Alpha M.O.S.

Altea Therapeutics

Alvogen

Amgen

Amylin Pharmaceuticals

Antares Pharma

Antigen Express Inc

Apotex Corp

Applied Pharma Research (APR)

Aptalis Pharma

Aptuit

Aradigm Corp

Arakis

Ascend Therapeutics

AstraZeneca

Axcan Intermediate Holdings (now Aptalis Pharma)

Battelle Memorial Institute

Bausch & Lomb

Organisations Mentioned in This Report

www.visiongain.com

Contents Baxter International

Bayer

Berna Biotech

Biocon

Biogen Idec

Bioject Medical Technologies

Biological E. Limited

Biotechpharma

Boehringer Ingelheim

Bristol-Myers Squibb

Cardinal Health

Catalent Pharma Solutions

Celgene Corporation

Cell Therapeutics

Cephalon

Chiron Corporation

Cima Labs (Cephalon)

Circassia

Columbia Laboratories

CSL Limited

CT Arzneimittel

Dendreon Corp.

Dr. Reddy's Laboratories

EKR Therapeutics

Elan Pharmaceuticals

Eli Lilly and Company

Elite Pharmaceuticals

Emisphere Technologies

Endo Pharmaceuticals

Ethypharm

www.visiongain.com

Contents Eurand Pharmaceuticals

Eurofarma

European Medicines Agency (EMA)

Ferring Pharmaceuticals

Flynn Pharma

Food and Drug Administration (US FDA)

Fresenius Group

Genentech (now part of Roche)

Generex Biotechnology Corporation

geneRx+

GeneScience Pharmaceuticals

Genmab

Genta

Genzyme Corporation

Gilead Sciences

GlaxoSmithKline (GSK)

Glide Pharma

Glycologic Limited

Hisamitsu Pharmaceutical Co.

Intercell

Janssen Biotech

Johnson & Johnson Services (J&J)

Labtec

Leiras OY (Nycomed)

LG Life Sciences

MannKind Corporation

Massachusetts Institute of Technology (MIT)

Medicines and Healthcare products Regulatory Agency (MHRA)

Merck & Co

Merck Serono

www.visiongain.com

Contents Minnesota Rubber and Plastics (MRP)

MonoSol Rx

MPI Research

MundiPharma

Mylan

NanoPass Technologies

National Institute for Health and Clinical Excellence (NICE, UK)

National Institute of Health (NIH, USA)

Nektar Therapeutics

Nordic Bioscience

Novartis Pharma

Noven Pharmaceuticals

Novo Nordisk

Novogyne Pharmaceuticals

Otsuka Pharmaceuticals Co.

Pacira Pharmaceutical

Par Pharmaceutical Companies

Pfizer

PharmaJet

Pre-clinical Partnerships

ProFibrix

pSivida Corp.

Ranbaxy Laboratories

Recipharm

Roche

Romark

Sandoz (now part of Novartis)

Sanofi (formally Sanofi-Aventis)

Schering-Plough Corporation (now part of Merck & Co.)

Shire

www.visiongain.com

Contents Sigma-Tau Pharmaceuticals

SkyePharma

Sosei Group Corp.

Spectrum Pharmaceuticals

Statens Serum Institut

Strativa Pharmaceuticals

Takeda Pharmaceutical Company

Team Consulting Ltd

Teva Pharmaceuticals Industries

The Blackstone Group

The United Nations Children's Fund (UNICEF)

TRION Pharma

UCB

University of Copenhagen, Denmark

US Department of Health and Human Services

Vectura Group

Vestiq Pharmaceuticals

Whitehall Laboratories

World Health Organization (WHO)

Wyeth (now a part of Pfizer Inc.)

Zhejiang CONBA Pharmaceutical Co.

Zogenix Technologies

www.visiongain.com


Visiongain believes that this class will show steady, low single-digit growth throughout the forecast

period, 2013 to 2023. Revenues will increase to $5.67bn in 2017 and $6.04bn in 2023 (Tables

4.15-4.16 and Figure 4.6). The initial growth of sales in this class will be due to steady increases in

sales of the current leading drugs. The introduction of new drugs will also contribute to growth of

this class, our analyses reveal. That product category will be a main revenue growth driver for drug

delivery technologies – products and services.

Source: visiongain 2013

Generic Name Brand Name CompanyEptacog alfa/ recombinant human coagulation Factor VIIa (rFVIIa) NovoSeven Novo Nordisk

Factor VIII Recombinate Baxter International

Factor VIII (procoagulant) Advate Baxter InternationalOctocog alfa Kogenate FS Bayer HealthCare

Factor VIII/ von Willebrand Factor Complex Humate P CSL BehringOctocog alfa Helixate FS CSL Behring

Factor VIII Xyntha Pfizer

Factor IX BeneFIX Pfizer

Factor VIII Koate-DVI Talecris Biotherapeutics

Factor VIII Monoclate-P CSL Behring

Factor VIII ReFacto PfizerFactor IX Mononine CSL Behring

Table 4.14 Some Recombinant Coagulation Factors, 2013


2012 2013 2014 2015 2016 2017Recombinant Coagulation Factors ($bn) 5.13 5.36 5.47 5.55 5.63 5.67Annual Growth (%) 6 4 2 1 2 1CAGR (%) 2.0

Source: visiongain 2013; CAGR values are for 2012-2017

www.visiongain.com


4.1.9 Other Therapeutic Proteins Other categories of therapeutic proteins include the following:

Human growth hormones

Immunosuppressant proteins

Enzyme replacements

Follicle stimulating hormones.

Some of the leading products in this category are available as lyophilised powder formulations that

require reconstitution before use. Many of the leading growth hormones are available in prefilled

Source: visiongain 2013

2018 2019 2020 2021 2022 2023Recombinant Coagulation Factors ($bn) 5.74 5.80 5.85 5.89 5.92 6.04Annual Growth (%) 1 1 1 1 1 2CAGR (%) 1.0


Figure 4.6 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2023

Source: visiongain 2013; CAGR values are for 2018-2023

5.1

5.4 5.5

5.5 5.6

5.7

5.7

5.8

5.9

5.9

5.9

6.0

4.6

4.8

5.0

5.2

5.4

5.6

5.8

6.0

6.2

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Sale

s ($

bn)

Year

Drug Delivery Technologies: Commercial Prospects 2013-2023

Health & Medicine

Transcript of Drug Delivery Technologies: Commercial Prospects 2013-2023